 |
|
Efficacy and Safety of Opioid Agonists in the Treatment of Neuropathic Pain of Nonmalignant Origin
Systematic Review and Meta-analysis of Randomized Controlled Trials
Elon Eisenberg, MD;
Ewan D. McNicol, RPh;
Daniel B. Carr, MD
JAMA. 2005;293:3043-3052.
Context In the United States, an estimated 2 million persons have neuropathic pain that is often resistant to therapy. The use of opioids for neuropathic pain remains controversial, in part because studies have been small, have yielded equivocal results, and have not established the long-term risk-benefit ratio of this treatment.
Objective To assess the efficacy and safety of opioid agonists for the treatment of neuropathic pain based on published randomized controlled trials (RCTs).
Data Sources We searched MEDLINE (1966 to December 2004) and the Cochrane Central Register of Controlled Trials (fourth quarter, 2004) for articles in any language, along with reference lists of reviews and retrieved articles, using a combination of 9 search terms for RCTs with 32 terms for opioids and 15 terms for neuropathic pain.
Study Selection Trials were included in which opioid agonists were given to treat central or peripheral neuropathic pain of any etiology, pain was assessed using validated instruments, and adverse events were reported. Studies in which drugs other than opioid agonists were combined with opioids or opioids were administered epidurally or intrathecally were excluded.
Data Extraction Data were extracted by 2 independent investigators and included demographic variables, diagnoses, interventions, efficacy, and adverse effects.
Data Synthesis Twenty-two articles met inclusion criteria and were classified as short-term (less than 24 hours; n = 14) or intermediate-term (median = 28 days; range = 8-56 days; n = 8) trials. The short-term trials had contradictory results. In contrast, all 8 intermediate-term trials demonstrated opioid efficacy for spontaneous neuropathic pain. A fixed-effects model meta-analysis of 6 intermediate-term studies showed mean posttreatment visual analog scale scores of pain intensity after opioids to be 14 units lower on a scale from 0 to 100 than after placebo (95% confidence interval [CI], –18 to –10; P<.001). According to number needed to harm (NNH), the most common adverse event was nausea (NNH, 3.6; 95% CI, 2.9-4.8), followed by constipation (NNH, 4.6; 95% CI, 3.4-7.1), drowsiness (NNH, 5.3; 95% CI, 3.7-8.3), vomiting (NNH, 6.2; 95% CI, 4.6-11.1), and dizziness (NNH, 6.7; 95% CI, 4.8-10.0).
Conclusions Short-term studies provide only equivocal evidence regarding the efficacy of opioids in reducing the intensity of neuropathic pain. Intermediate-term studies demonstrate significant efficacy of opioids over placebo for neuropathic pain, which is likely to be clinically important. Reported adverse events of opioids are common but not life-threatening. Further RCTs are needed to establish their long-term efficacy, safety (including addiction potential), and effects on quality of life.
Author Affiliations: Pain Relief Unit, Rambam Medical Center, and Haifa Pain Research Group, the Technion-Israel Institute of Technology, Haifa, Israel (Dr Eisenberg); Department of Anesthesia (Mr McNicol and Dr Carr), Pharmacy Department (Mr McNicol), and Division of Clinical Care Research (Dr Carr), Tufts–New England Medical Center and Tufts University School of Medicine, Boston, Mass. Dr Carr is now with Innovative Drug Delivery Systems Inc, New York, NY.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A Comparison of Long- and Short-Acting Opioids for the Treatment of Chronic Noncancer Pain: Tailoring Therapy to Meet Patient Needs
Argoff and Silvershein
Mayo Clin Proc. 2009;84:602-612.
ABSTRACT
| FULL TEXT
Management of Neuropathic Cancer Pain Following WHO Analgesic Ladder: A Prospective Study
Mishra et al.
AM J HOSP PALLIAT CARE 2009;25:447-451.
ABSTRACT
Incidence and Management of Phantom Limb Pain According to World Health Organization Analgesic Ladder in Amputees of Malignant Origin
Mishra et al.
AM J HOSP PALLIAT CARE 2008;24:455-462.
ABSTRACT
Medication and treatment use in primary care patients with chronic pain of predominantly neuropathic origin
Torrance et al.
Fam Pract 2007;24:481-485.
ABSTRACT
| FULL TEXT
Clinical Experience with Transdermal and Orally Administered Opioids in Palliative Care Patients--A Retrospective Study
Clemens and Klaschik
Jpn J Clin Oncol 2007;0:hym017v1-8.
ABSTRACT
| FULL TEXT
Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial
Abrams et al.
Neurology 2007;68:515-521.
ABSTRACT
| FULL TEXT
Systematic Review: Opioid Treatment for Chronic Back Pain: Prevalence, Efficacy, and Association with Addiction
Martell et al.
ANN INTERN MED 2007;146:116-127.
ABSTRACT
| FULL TEXT
New perspectives on the management of diabetic peripheral neuropathic pain
Jensen et al.
Diabetes and Vascular Disease Research 2006;3:108-119.
ABSTRACT
Neuropathic pain: a practical guide for the clinician.
Gilron et al.
CMAJ 2006;175:265-275.
ABSTRACT
| FULL TEXT
Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects.
Furlan et al.
CMAJ 2006;174:1589-1594.
ABSTRACT
| FULL TEXT
Oxycodone for Cancer-Related Pain: Meta-analysis of Randomized Controlled Trials.
Reid et al.
Arch Intern Med 2006;166:837-843.
ABSTRACT
| FULL TEXT
Different Effects of Opioid and Cannabinoid Receptor Agonists on C-Fiber-Induced Extracellular Signal-Regulated Kinase Activation in Dorsal Horn Neurons in Normal and Spinal Nerve-Ligated Rats
Kawasaki et al.
J. Pharmacol. Exp. Ther. 2006;316:601-607.
ABSTRACT
| FULL TEXT
Are Opioids Effective for Neuropathic Pain?
JWatch Psychiatry 2005;2005:9-9.
FULL TEXT
Are Opioids Effective for Neuropathic Pain?
JWatch Neurology 2005;2005:9-9.
FULL TEXT
What's new in the other general journals
Tonks
BMJ 2005;331:71-72.
FULL TEXT
|
